



For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Editor's Choice** – Revised Programs: Bendamustine with or without Rituximab for Indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma (ULYBENDR, ULYBEND); BCCA Website Unavailable – Saturday, April 9th
- **Medication Safety Corner** – Revision of the BCCA TALLman Lettering List
- **Cancer Drug Manual** – Revised: Eribulin, Cisplatin, Doxorubicin, Mitomycin, Oxaliplatin, Paclitaxel; Editorial Board Membership
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts** – New: LULACATRT; Revised: LULACATRT, ULYBEND, ULYBENDR, LYRMTN
- **Website Resources and Contact Information**

EDITOR'S CHOICE

REVISED PROGRAMS

The BCCA Provincial Systemic Therapy Program has revised the following programs effective 1 April 2016:

Lymphoma:

Bendamustine with or without Rituximab for Indolent Non-Hodgkin Lymphoma (NHL) and Mantle Cell Lymphoma (ULYBENDR, ULYBEND) – The BCCA Lymphoma Tumour Group has revised the eligibility criteria of ULYBENDR and ULYBEND to be consistent with the indications supported by the pan-Canadian Oncology Drug Review (pCODR). Bendamustine with rituximab is now approved for the treatment of relapsed/refractory indolent NHL and mantle cell lymphoma in any line of therapy. Single-agent bendamustine is also approved in this setting in patients who were refractory or intolerant to rituximab. There is no longer a requirement for patients to have failed prior BCCA standard treatment (e.g. involved field radiation, alkylating agents, purine analogues or gemcitabine) to be eligible for bendamustine in the treatment of relapsed/refractory indolent NHL and mantle cell lymphoma.

BCCA WEBSITE UNAVAILABLE – SATURDAY, APRIL 9TH

Please note that the BCCA website will not be available on Saturday, April 9th between 6 am to 1 pm due to scheduled maintenance.

MEDICATION SAFETY CORNER

REVISION OF BCCA TALLMAN LETTERING LIST

In 2011, the BCCA implemented the Provincial Pharmacy Directive, “*Use of TALLman Lettering for Medication Nomenclature*”, to help prevent errors stemming from look-alike/sound-alike drugs. The directive has recently been updated using the following hierarchy of information:

1. Institute for Safe Medication Practices (ISMP) Canada recommendations
2. ISMP US recommendations
3. Clinical and Systems Transformation (CST) project requirements that are standardized across Provincial Health Services, Vancouver Coastal Health, and Providence Health Authorities

Examples of new ISMP Canada recommendations based on targeted look-alike/sound-alike, high-alert medications include:¹

iBRUtinib/iMAtinib
PANitumumab/ PERTuzumab

The incorporation of the revised TALLman list into BCCA documentations and databases will occur gradually over the next few months. BCCA staff may access the revised Provincial Pharmacy Directive in the BCCA internal drive at: H:\EVERYONE\Pharmacy\BCCA Pharmacy Directives\VI_RiskManagement\VI-90 Medication Nomenclature. To learn more about the BCCA TALLman lettering initiative, please see the [March 2011](#) issue of the Systemic Therapy Update.

Reference:

1. ISMP Canada safety bulletin. Oct 30, 2015; 15(10):1-4. Available at: www.ismp-canada.org/download/safetyBulletins.

CANCER DRUG MANUAL

REVISED MONOGRAPHS AND PATIENT HANDOUTS

Eribulin Monograph

- *Dosage Guidelines* section – updated dosing recommendations in renal failure and expanded the dosage range for adults

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) has been added to the *Parenteral Administration* table in the following monographs:

- Cisplatin
- Doxorubicin
- Mitomycin
- Oxaliplatin
- Paclitaxel

EDITORIAL BOARD MEMBERSHIP

The Cancer Drug Manual Team would like to welcome Dennis Jang to the CDM Editorial Board. Dennis is the Pharmacy Drug Distribution Coordinator for the BCCA – Vancouver Centre. Welcome Dennis!

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring BCCA Compassionate Access Program approval are prefixed with the letter “U”.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Protocol Title
LULACATRT	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Treatment of Locally Advanced Non-Small Cell Lung Cancer using CARBOplatin and PACLitaxel with Radiation Therapy

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
LULACATRT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Consolidation chemotherapy clarified</i>	Treatment of Locally Advanced Non-Small Cell Lung Cancer using CARBOplatin and PACLitaxel with Radiation Therapy
ULYBEND	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility revised</i>	Treatment of Non-Hodgkin Lymphoma with Bendamustine
ULYBENDR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility revised</i>	Treatment of Non-Hodgkin Lymphoma with Bendamustine and riTUXimab
LYRMTN	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Timing of blood work revised</i>	Maintenance riTUXimab for Indolent Lymphoma

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	www.bccancer.bc.ca
Systemic Therapy Update	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy/systemic-therapy-update
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
Cancer Drug Manual	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual
Cancer Management Guidelines	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines
Cancer Chemotherapy Protocols, Pre-printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
CON Pharmacy Educators	www.bccancer.bc.ca/health-professionals/professional-resources/pharmacy

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor			bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update the contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604-877-6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604-675-8003 Toll Free 888-675-8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247		mclin@bccancer.bc.ca
Nursing Professional Practice	604-877-6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888-355-0355	604-708-2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604-877-6277	604-708-2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250-712-3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604-851-4710 Toll Free 877-547-3777		
BCCA-Centre for the North	250-645-7300 Toll Free 888-775-7300		
BCCA-Fraser Valley Centre	604-930-2098 Toll Free 800-523-2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250-712-3900 Toll Free 888-563-7773		
BCCA-Vancouver Centre	604-877-6000 Toll Free 800-663-3333		
BCCA-Vancouver Island Centre	250-519-5500 Toll Free 800-670-3322		

EDITORIAL REVIEW BOARD

Sally Waignein, PharmD (Editor)
 Mário de Lemos, PharmD, MSc (Oncol)
 Caroline Lohrisch, MD
 Robert Crisp, BScPT, MBA

Beth Morrison, MLS
 Ava Hatcher, RN BN CONc
 Rob Watt, BSc(Pharm)